본문으로 건너뛰기
← 뒤로

Proposal on incorporating consolidation-to-tumor ratio into the clinical T1 classification in patients with invasive lung adenocarcinoma.

1/5 보강
Translational lung cancer research 📖 저널 OA 100% 2026 Vol.15(3) p. 51
Retraction 확인
출처

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
환자: part-solid nodules (PSNs) remains ambiguous
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] CTR had a significant effect on the prognosis of PSNs, even when the solid component sizes were similar. An exploratory staging model incorporating CTR showed potential for improving risk stratification over the current T1 classification, but warrants external validation in future studies.

Zhang M, Deng C, Fu F, Ye T, Turna A, Li Y, Zhang Y, Chen H

📝 환자 설명용 한 줄

[BACKGROUND] The prognostic implication of consolidation-to-tumor ratio (CTR) in patients with part-solid nodules (PSNs) remains ambiguous.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P<0.001
  • 추적기간 80.5 months

이 논문을 인용하기

↓ .bib ↓ .ris
APA Zhang M, Deng C, et al. (2026). Proposal on incorporating consolidation-to-tumor ratio into the clinical T1 classification in patients with invasive lung adenocarcinoma.. Translational lung cancer research, 15(3), 51. https://doi.org/10.21037/tlcr-2025-aw-1274
MLA Zhang M, et al.. "Proposal on incorporating consolidation-to-tumor ratio into the clinical T1 classification in patients with invasive lung adenocarcinoma.." Translational lung cancer research, vol. 15, no. 3, 2026, pp. 51.
PMID 41982683

Abstract

[BACKGROUND] The prognostic implication of consolidation-to-tumor ratio (CTR) in patients with part-solid nodules (PSNs) remains ambiguous. The aim of this study is to explore the potential of CTR for refining prognostic stratification within the current clinical T1 classification.

[METHODS] There were 1,340 N0M0 lung adenocarcinoma (LUAD) patients with PSNs (solid size ≤3 cm) enrolled. We constructed a novel risk stratification model based on both solid component size and CTR. The lung cancer-specific survival (LCSS) and recurrence-free survival (RFS) rates of the patients in the current and modified staging groups were evaluated.

[RESULTS] At a median follow-up of 80.5 months, there were 89 recurrences and 40 lung cancer-associated deaths. The 5-year LCSS and RFS rates differed significantly in patients divided by CTR (0< CTR ≤0.5 . 0.5< CTR ≤0.8, LCSS: P<0.001, RFS: P<0.001; 0.5< CTR ≤0.8 . 0.8< CTR <1, LCSS: P=0.002, RFS: P<0.001). Subgroup analysis showed that a larger CTR was associated with worse prognosis in each clinical T1 classification (T1a: CTR ≤0.5 . CTR >0.5, P=0.03; T1b: CTR ≤0.5 . CTR >0.5, P=0.006; T1c: CTR ≤0.8 . CTR >0.8, P=0.04). The CTR-incorporated stratification scheme clearly classified the prognosis of PSNs (LCSS: T1mi: 100%, T1a: 99.1%, T1b: 89.4%, T1c: 75.3%; RFS: T1mi: 100%, T1a: 98.2%, T1b: 87.6%, T1c: 66.9%).

[CONCLUSIONS] CTR had a significant effect on the prognosis of PSNs, even when the solid component sizes were similar. An exploratory staging model incorporating CTR showed potential for improving risk stratification over the current T1 classification, but warrants external validation in future studies.

🏷️ 키워드 / MeSH

같은 제1저자의 인용 많은 논문 (5)

🟢 PMC 전문 열기